Spotlight
Video

Can we target KRAS effectively in advanced NSCLC?

cancergrace has 804 videos Subscribe Here

Loading........
Description: http://cancerGRACE.org/...

Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

GRACEcastUC 144 Lung
Shared By : cancergrace
Posted on : 07/03/13
Added : 4 years ago
Category : Other